Pioglitazone 15 mg is a medication used to treat type 2 diabetes. It belongs to a class of drugs known as thiazolidinediones, which work by helping the body use insulin more effectively. Pioglitazone 15 mg is also known as Actos and is available in tablet form. It is usually prescribed to be taken once a day, although the exact dosage and duration of treatment will depend on the individual. Taking pioglitazone 15 mg can help to improve blood sugar control and reduce the risk of long-term complications associated with diabetes, such as heart disease, stroke, and kidney damage.
Pioglitazone 15 mg works by increasing the body’s sensitivity to insulin. Insulin is a hormone produced by the pancreas that helps the body to use glucose (sugar) from food for energy. In people with type 2 diabetes, the body's cells become resistant to the effects of insulin, meaning that the pancreas has to produce more insulin to keep blood sugar levels stable. By increasing the body’s sensitivity to insulin, pioglitazone 15 mg helps the pancreas to produce less insulin, which can help to improve blood sugar control.
Taking pioglitazone 15 mg can help to improve blood sugar control and reduce the risk of long-term complications associated with diabetes. Specifically, pioglitazone 15 mg can help to: • Lower blood sugar levels • Reduce the risk of heart disease • Reduce the risk of stroke • Reduce the risk of kidney damage • Reduce the risk of nerve damage • Reduce the risk of eye damage • Reduce the risk of amputation • Reduce the risk of death from diabetes-related complications
Pioglitazone 15 mg is usually prescribed to people with type 2 diabetes who have not been able to control their blood sugar levels with diet and exercise alone. It is also sometimes prescribed to people with type 2 diabetes who are taking other medications to help control their blood sugar levels.
Like all medications, pioglitazone 15 mg can cause side effects. The most common side effects include: • Weight gain • Swelling in the hands and feet • Headache • Diarrhea • Nausea • Muscle pain • Weakness More serious side effects, such as an increased risk of heart failure, have been reported in some people taking pioglitazone 15 mg. If you experience any of these side effects, you should talk to your doctor as soon as possible.
Pioglitazone 15 mg is a medication used to treat type 2 diabetes. It works by increasing the body’s sensitivity to insulin, which can help to improve blood sugar control and reduce the risk of long-term complications associated with diabetes. Taking pioglitazone 15 mg can also help to reduce the risk of heart disease, stroke, kidney damage, nerve damage, eye damage, amputation, and death from diabetes-related complications. Pioglitazone 15 mg is usually prescribed to people with type 2 diabetes who have not been able to control their blood sugar levels with diet and exercise alone. Although it can be effective, it can also cause side effects, such as weight gain, swelling in the hands and feet, headache, diarrhea, nausea, muscle pain, and weakness. If you experience any of these side effects, you should talk to your doctor as soon as possible.
1.
Belgian Algorithm Reshapes Endometrial Cancer Care
2.
ASCO: Durvalumab plus FLOT beneficial for resectable gastric, GE junction cancer
3.
Nuclear missile workers are contracting cancer: They blame the bases
4.
On all CAR-T products, the FDA is calling for a new boxed warning.
5.
ASCO Future Focus: Metastatic Breast Cancer: Future Focus from the American Society of Clinical Oncology
1.
Understanding SVR Normal Range: A Guide to Achieving Optimal Health
2.
Consensus Recommendations for Healthy Hematologic Aging
3.
The Role of Alanine Aminotransferase in Liver Health and Disease
4.
Neoepitope Vaccines in Oncology: Precision, Sequencing, and Immunotherapy Frontiers
5.
Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Efficient Management of First line ALK-rearranged NSCLC - Part II
2.
A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC
3.
Understanding the Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- PALOMA 2 Study.
4.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
5.
Should We Use DARA Up Front As First-Line Therapy in MM? - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation